The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for enasidenib (Celgene Pty Ltd)
Active ingredients
enasidenib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Tablet, film-coated
Indication
For the treatment of patients with acute myeloid leukaemia with an isocitrate dehydrogenase-2 (IDH2) mutation.